Orchestra BioMed insider purchase lifts CEO stake to 903k shares

Rhea-AI Filing Summary

Orchestra BioMed Holdings (OBIO) – Form 4 insider activity

On 08/04/2025, Chief Executive Officer & Chairperson David P. Hochman purchased 20,000 common shares in the company’s underwritten public offering at $2.75 per share, investing $55,000. The shares were bought indirectly through the DPH 2008 Trust, raising that trust’s position to 349,331 shares.

Following the acquisition, Hochman’s total beneficial ownership stands at 903,931 shares, consisting of 545,460 shares held directly and 358,471 shares held through five family trusts (DPH 2008, Solomon Ascher 2019, Hannah 2019, Judah Herman 2019, NSH 2008). No shares were sold and no derivative securities were reported in the filing.

The transaction increases the CEO’s economic exposure and signals participation in the recent capital raise, but the filing contains no financial results, guidance, or other operational disclosures.

Positive

• CEO insider purchase: 20,000 shares acquired at $2.75 in public offering, demonstrating management confidence.
• Total holdings increase: Beneficial ownership rises to approximately 903,931 shares, aligning interests with shareholders.
• No sales or derivatives: Filing reports only acquisitions, with zero dispositions or complex instruments.

Negative

• None.

Insights

Securities Analyst

TL;DR: CEO buys 20k shares at $2.75, lifting total stake to ~904k; modestly positive signal, no disposals or derivatives.

The direct participation of the CEO in the public offering indicates incremental insider confidence and aligns leadership interests with shareholders. While the dollar amount ($55k) is small relative to his existing stake, the absence of any sales and the continued accumulation during an equity raise are constructive from a sentiment standpoint. No material downside information accompanies the filing, so market impact should be mildly positive but limited by the transaction’s modest size.

Corporate Governance Expert

TL;DR: Insider purchase through family trust enhances alignment; governance posture unchanged, impact positive but not transformative.

Hochman’s use of long-standing family trusts preserves transparency and keeps voting power consolidated. The filing shows proper Section 16 compliance and no complex derivative structures, reducing governance risk. Although the purchase is not large enough to materially alter control dynamics, it reinforces commitment during capital formation. I classify the governance impact as positive, with low risk of adverse interpretation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hochman David P

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PA 18938

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share ("Common Stock")	08/04/2025		P		20,000	A	$2.75(1)	349,331	I	By the DPH 2008 Trust
Common Stock								545,460	D
Common Stock								2,000	I	By the Solomon Ascher Hochman 2019 Trust
Common Stock								2,000	I	By the Hannah Hochman 2019 Trust
Common Stock								2,000	I	By the Judah Herman Hochman 2019 Trust
Common Stock								3,140	I	By the NSH 2008 Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were purchased in an underwritten public offering of the Issuer at the public offering price of $2.75 per share.

Remarks:

Chief Executive Officer and Chairperson

	/s/ Andrew Taylor, Attorney-in-Fact	08/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many OBIO shares did CEO David P. Hochman buy on 08/04/2025?

20,000 common shares were purchased.

What price did the OBIO shares cost in the insider transaction?

The shares were bought at $2.75 per share during an underwritten public offering.

What is the CEO’s total beneficial ownership after the Form 4 transaction?

David P. Hochman now beneficially owns approximately 903,931 shares of OBIO.

Did the insider sell any OBIO shares in this Form 4 filing?

No. Only purchases were reported; there were no dispositions.

Were any derivative securities involved in the filing?

No. No options, warrants, or other derivatives were reported.

What trusts hold the insider’s indirect OBIO ownership?

Shares are held by the DPH 2008 Trust and four 2019/2008 family trusts for Solomon Ascher, Hannah, Judah Herman, and NSH.